Inhibitors of Leishmania GDP-mannose pyrophosphorylase identified by high-throughput screening of small-molecule chemical library

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 5, 2010, Pages 1712-1719

  Lackovic, Kurt ^a   Parisot, John P ^a   Sleebs, Nerida ^a   Baell, Jonathan B ^a   Debien, Laurent ^a   Watson, Keith G ^a   Curtis, Joan M ^a   Handman, Emanuela ^a   Street, Ian P ^a   Kedzierski, Lukasz ^a  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEISHMANIAL AGENT; MANNOSE 1 PHOSPHATE GUANYLYLTRANSFERASE; PHOSPHATE; UNCLASSIFIED DRUG;

AMASTIGOTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ASSAY; CHEMICAL STRUCTURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG SCREENING; EX VIVO STUDY; FIBROBLAST; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IC 50; LEISHMANIA; MACROPHAGE; MAMMAL CELL; MOLECULAR LIBRARY; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SENSOR; STRUCTURE ACTIVITY RELATION;

ANTIPROTOZOAL AGENTS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; ENZYME INHIBITORS; FIBROBLASTS; HUMANS; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; NUCLEOTIDYLTRANSFERASES; PYRAZOLES; QUINOLINES; SMALL MOLECULE LIBRARIES; THIADIAZOLES;

EID: 77951217893     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01634-09     Document Type: Article

References (33)

1. Reference deleted.
2. Armutlu, P., M. E. Ozdemir, S. Ozdas, I. H. Kavakli, and M. Turkay. 2009. Discovery of novel CYP17 inhibitors for the treatment of prostate cancer with structure-based design. Lett. Drug Des. Discov. 6:337-344.
3. Baell, J. B., and G. A. Holloway. 2010. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J. Med. Chem. [Epub ahead of print.] doi:10.1021/jm901137j.
4. Bertucci, A., A. Innocenti, D. Zoccola, A. Scozzafava, S. Tambutte, and C. T. Supuran. 2009. Carbonic anhydrase inhibitors. Inhibition studies of a coral secretory isoform by sulfonamides. Bioorg. Med. Chem. 17:5054-5058.
5. Cheeseright, T. J., M. Holm, F. Lehmann, S. Luik, M. Gottert, J. L. Melville, and S. Laufer. 2009. Novel lead structures for p38 MAP kinase via Field-Screen virtual screening. J. Med. Chem. 52:4200-4209.
6. Cruz, I., J. Nieto, J. Moreno, C. Canavate, P. Desjeux, and J. Alvar. 2006. Leishmania/HIV co-infections in the second decade. Indian J. Med. Res. 123:357-388.
7. Davis, A. J., and L. Kedzierski. 2005. Recent advances in antileishmanial drug development. Curr. Opin. Invest. Drugs 6:163-169.
8. Davis, A. J., M. A. Perugini, B. J. Smith, J. D. Stewart, T. Ilg, A. N. Hodder, and E. Handman. 2004. Properties of GDP-mannose pyrophosphorylase, a critical enzyme and drug target in Leishmania mexicana. J. Biol. Chem. 279:12462-12468.
9. Freeze, H. H., and M. Aebi. 1999. Molecular basis of carbohydrate- deficient glycoprotein syndromes type I with normal phosphomannomutase activity. Biochim. Biophys. Acta 1455:167-178.
10. Garami, A., and T. Ilg. 2001. Disruption of mannose activation in Leishmania mexicana: GDP-mannose pyrophosphorylase is required for virulence, but not for viability. EMBO J. 20:3657-3666.
11. Garami, A., A. Mehlert, and T. Ilg. 2001. Glycosylation defects and virulence phenotypes of Leishmania mexicana phosphomannomutase and dolicholphosphate-mannose synthase gene deletion mutants. Mol. Cell. Biol. 21: 8168-8183.
12. Glaser, T. A., S. J. Wells, T. W. Spithill, J. M. Pettitt, D. C. Humphris, and A. J. Mukkada. 1990. Leishmania major and L. donovani: a method for rapid purification of amastigotes. Exp. Parasitol. 71:343-345.
13. Handman, E. 1999. Cell biology of Leishmania. Adv. Parasitol. 44:1-39.
14. Hilfiker, M. A., N. Wang, X. Hou, Z. Du, M. A. Pullen, M. Nord, R. Nagilla, H. E. Fries, C. W. Wu, A. C. Sulpizio, J. P. Jaworski, D. Morrow, R. M. Edwards, and J. Jin. 2009. Discovery of novel aminothiadiazole amides as selective EP(3) receptor antagonists. Bioorg. Med. Chem. Lett. 19:4292-4295.
15. Hirshberg, M., K. Henrick, L. L. Haire, N. Vasisht, M. Brune, J. E. Corrie, and M. R. Webb. 1998. Crystal structure of phosphate binding protein labeled with a coumarin fluorophore, a probe for inorganic phosphate. Biochemistry (Mosc.) 37:10381-10385.
16. Hodgkinson, V. H., and L. Soong. 1997. In vitro maintenance of Leishmania amastigotes directly from lesions: advantages and limitations. J. Parasitol. 83:953-956.
17. Holloway, G. A., J. B. Baell, A. H. Fairlamb, P. M. Novello, J. P. Parisot, J. Richardson, K. G. Watson, and I. P. Street. 2007. Discovery of 2-iminobenzimidazoles as a new class of trypanothione reductase inhibitor by high-throughput screening. Bioorg. Med. Chem. Lett. 17:1422-1427.
18. Holloway, G. A., W. N. Charman, A. H. Fairlamb, R. Brun, M. Kaiser, E. Kostewicz, P. M. Novello, J. P. Parisot, J. Richardson, I. P. Street, K. G. Watson, and J. B. Baell. 2009. Trypanothione reductase high-throughput screening campaign identifies novel classes of inhibitors with antiparasitic activity. Antimicrob. Agents Chemother. 53:2824-2833.
19. Hopkins, A. L., C. R. Groom, and A. Alex. 2004. Ligand efficiency: a useful metric for lead selection. Drug Discov. Today 9:430-431.
20. Kedzierski, L., J. M. Curtis, M. Kaminska, J. Jodynis-Liebert, and M. Murias. 2007. In vitro antileishmanial activity of resveratrol and its hydroxylated analogues against Leishmania major promastigotes and amastigotes. Parasitol. Res. 102:91-97.
21. Kedzierski, L., R. L. Malby, B. J. Smith, M. A. Perugini, A. N. Hodder, T. Ilg, P. M. Colman, and E. Handman. 2006. Structure of Leishmania mexicana phosphomannomutase highlights similarities with human isoforms. J. Mol. Biol. 363:215-227.
22. Kedzierski, L., A. Sakthianandeswaren, J. M. Curtis, P. C. Andrews, P. C. Junk, and K. Kedzierska. 2009. Leishmaniasis: current treatment and prospects for new drugs and vaccines. Curr. Med. Chem. 16:599-614.
23. Ko, S., M. K. Lee, D. Shin, and H. Park. 2009. Structure-based virtual screening approach to the discovery of novel inhibitors of factor-inhibiting HIF-1: identification of new chelating groups for the active-site ferrous ion. Bioorg. Med. Chem. 17:7769-7774.
24. Lipinski, C. A., F. Lombardo, B. W. Dominy, and P. J. Feeney. 2001. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46:3-26.
25. Mitchell, M. S. 2003. Combinations of anticancer drugs and immunotherapy. Cancer Immunol. Immunother. 52:686-692.
26. Oprea, T. I., A. M. Davis, S. J. Teague, and P. D. Leeson. 2001. Is there a difference between leads and drugs? A historical perspective. J. Chem. Infect. Comput. Sci. 41:1308-1315.
27. Rabello, A., M. Orsini, and J. Disch. 2003. Leishmania/HIV co-infection in Brazil: an appraisal. Ann. Trop. Med. Parasitol. 97(Suppl. 1):17-28.
28. Segura-Cabrera, A., and M. A. Rodriguez-Perez. 2008. Structure-based prediction of Mycobacterium tuberculosis shikimate kinase inhibitors by high-throughput virtual screening. Bioorg. Med. Chem. Lett. 18:3152-3157.
29. St. George, S., J. V. Bishop, R. G. Titus, and C. P. Selitrennikoff. 2006. Novel compounds active against Leishmania major. Antimicrob. Agents Chemother. 50:474-479.
30. Vermeersch, M., R. Inocencio da Luz, K. Tote, J. P. Timmermans, P. Cos, and L. Maes. 2009. In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: practical relevance of stage-specific differences. Antimicrob. Agents Chemother. 53: 3855-3859.
31. von Stebut, E., Y. Belkaid, T. Jakob, D. L. Sacks, and M. C. Udey. 1998. Uptake of Leishmania major amastigotes results in activation and interleukin 12 release from murine skin-derived dendritic cells: implications for the initiation of anti-Leishmania immunity. J. Exp. Med. 188:1547-1552.
32. Weikert, R. J., S. Bingham, M. A. Emanuel, E. B. Fraser-Smith, D. G. Loughhead, P. H. Nelson, and A. L. Poulton. 1991. Synthesis and anthelmintic activity of 3′-benzoylurea derivatives of 6-phenyl-2,3,5,6- tetrahydroimidazo [2,1-b]thiazole. J. Med. Chem. 34:1630-1633.
33. World Health Organization. 2008. Initiative for vaccine research - leishmaniasis. World Health Organization, Geneva, Switzerland. http://www.who.int/vaccine-research/diseases/soa-parasitic/en/index3.html.